A rare cause of cutanous vasculitis: Anastrosole

Breast cancer is the most frequently diagnosed type of cancer and the foremost reason of the death of women from cancer. Hormone receptor positive breast cancer is the most frequent type of breast cancer. Anastrosole is one of the aromatase inhibitors which is indicated for early stage of hormone receptor positive breast cancer of postmenopausal women. A 67-year-old woman was refered to Rheumatology Department from Medical Oncology Department for skin rashes which have started 3 months ago. In her medical history, she was diagnosed as infiltrative ductal carcinoma grade-2 in the right breast. She had a modified radical mastectomy operation for the right breast and subsequently, anastrosole was started as her hormone receptor was found positive in histopathological examination. The drug was stopped after 5 years by her oncologist however she went on using the drug on her own demand. Three months before her referral, non-itchy, painless reddish rash was started on legs and arms. After careful physical and laboratory examination and histopathologic alevaluation, she was diagnosed as middle-vessel necrotising vasculitis. Anastrosole was stopped. Steroid and azathyoprine were started. On the fifth month of therapy, all skin lesions were resolved with postinflammatory hyperpigmentation. No additional problem was met. This case report is suggesting that, anastrosole which is a frequently preferred agent in recentyears, could also cause leucocytoclastic vasculits. Very rare cases with cutanous vasculitis were previously presented. This case report suggests that, during the management of patients under anastrosole therapy, cutanous vasculitis should be monitored carefully. [Cukurova Med J 2014; 39(2.000): 369-372

The value of immunophenotyping and T-cell receptor gamma gene rearrengement in the diagnosis of mycosis fungoides

WOS: 000249454601297

Multifocal Epitheloid Hemangioendothelioma: A Case Report

Epitheloid hemangioendothelioma (EHE) is a rare vascular tumor with malignant biological behavior. It arises from vascular endothelial cells, usually within soft tissues, and can occur in almost all locations, but tumor can be found in liver, lungs, bone and skin. It is considered to be a low or borderline malignant tumor with, usually, slow progression, but aggressive forms have been described. We present a 24 year-old female case of multifocal epitheloid hemangioendothelioma of the soft tissue with its clinical, radiological and histopathological findings [Cukurova Med J 2014; 39(2.000): 383-386

Chromosomal aberrations in multiple myeloma: clinical outcome and response to bortezomib

WOS: 000480626400012Purpose: Multiple myeloma is a heterogeneous disease, for which an understanding of the prognostic and predictive value of chromosomal aberrations is necessary to prescribe the most appropriate therapy. We aimed to document the frequencies of chromosomal aberrations in our institute and searched the relationships between therapy regimens and chromosomal aberrations. Materials and Methods: We analyzed the frequency of del(17p13), del(13q14), t(11;14), and t(4; 14) in patients with MM by interphase-fluorescent in situ hybridization who were diagnosed between January 2010 and December 2015 in our institute. We researched the relationship between response to conventional chemotherapy and Bortezomib based chemotherapy. Results: Eighty patients (72.7%) had at least one chromosomal aberration. The most frequently observed aberration was del(17p13) (48.2%), followed by del(13q14) (40.9%), t(11; 14) (16.4%), and t(4; 14) (11.8%). In clinically analyzed subgroup (n=67), 36 patients who received Bortezomib based chemotherapy showed a higher response rate (55.6%) than conventional chemotherapy group (48.4%). With respect to chromosomal aberrations, response rates were higher in Bortezomib based therapy group (63.2%) than conventional chemotherapy group (50%) in del (17p13) positive patients as well as in del (13q14) positive patients (61.5% in Bortezomib based, 50% in conventional chemotherapy group). Conclusion: Bortezomib-containing regimens may have beneficial effects on the clinical outcome of patients with del (17p13) and del (13q14)

Expression of PTEN, Akt, MAPK, p53, p95 for predicting trastuzumab resistance in breast cancer.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 01-06, 2012 -- Chicago, ILWOS: 000318009800235…Amer Soc Clin Onco

Histopathologic subtypes of pediatric lymphomas and relation to Ebstein-Barr virus: an immunohistochemical and in-situ hybridization study

WOS: 000437951900014Purpose: The aim of this study was toexplore the histopathologic subtypes of pediatric lymphomas and their relation with Ebstein-Barr virus infection in our region. Materials and Methods: In this retrospective study, 87 children including 36 cases with Hodgkin lymphoma and 51 cases with non-Hodgkin lymphoma were included in the study. The pathologic slides were used to investigate immunohistochemical staining with ebstein-barr virus latent membrane protein-1 and in-situ hybridization. Results: The most common histopathological subtype in hodgkin lymphoma cases was mixed cellular classical hodgkin lymphoma (55.6%). The most common histopathological subtype in Non-Hodgkin lymphoma cases was Burkitt lymphoma (51.0%). Ebstein-Barr virus latent membrane protein-1 was positive in 29 Hodgkin lymphoma. All non-Hodgkin lymphoma cases were stained negative with immunohistochemical. The positive staining rate of Hodgkin lymphoma cases with in-situ hybridization was 83.3% and this rate was 27.5% in non-Hodgkin lymphoma cases. The differences between groups for both staining methods were significant. Conclusion: The results of this study show that the distribution of histopatholojik subtypes of pediatric lymphomas similar to in developing countries. And we have observed that in-situ hybridization is more specific than immunohistochemistry because Ebstein-Barr virus positivity is more detected in in-situ hybridization

MicroRNA profiles (including 370 miRNAs) in lymphomas.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2013 -- Chicago, ILWOS: 000335419604701…Amer Soc Clin Onco

THE PROTECTIVE EFFECTS OF PHOSPHO-DIESTERASE-4-SPECIFIC INHIBITOR ROLIPRAM ON ACUTE ISCHEMIA-REPERFUSION INJURY IN RAT KIDNEY

WOS: 000308488200012

The Effect of Deferoxamine on Superoxide Dismutase and Histopathological Changes Following Experimental Spinal Cord Injury

WOS: 000361529400009Aim: Primary traumatic spinal cord injury is defined as the injury occurring at the time of the trauma. The metabolic and biochemical processes lead to the secondary trauma in the following hours after the primary trauma. Free radicals and ischemic reperfusion injury are two factors which play role in secondary injury. An iron chelating agent deferoxamine has treatment effect on secondary injury mechanisms by binding free iron ion. This study is based on these effects of deferoxamine. Material and Methods: The experimental spinal cord injury model was applied on 26 rats. In control group I, 10 rats were sacrificed to provide normal spinal cord histopathology and biochemical baseline values. In group II, 6 rats underwent six segment laminectomy and spinal cord injury was produced by extradural compression of the exposed cord by aneurysm clip. Same procedures were performed in 10 rats in group III, but they also received 100mg/kg/day intraperitoneal injection of deferoxamine. Group II and III were sacrificed at 48 hours after the trauma. The effect of deferoxamine on superoxide dismutase and histopathological findings were studied. Results: Superoxide dismutase values of the treatment group were found to decrease significantly when compared to the trauma group. The histopathological evaluation revealed the preservation of spinal cord structure in the treatment group. Conclusion: Results showed that deferoxamine, might reduce secondary injury in damaged rat spinal cord tissue, by a possible mechanism of decreasing the production of free radicals

Critical time point for apoptotic cell death in an experimental ischemia/reperfusion model and the effect of N-acetylcystein

WOS: 000405121500004Objective: Kidney transplantation is an important treatment option in end stage renal failure. Tissue death may be an important problem when a kidney is removed from a cadaver and transported to a donor a long distance away. The purpose of this study is to determine the critical time point for apoptotic cell death in a renal ischemia/reperfusion model and determine the effects of N-acetylcystein on apoptosis induced by ischemia injury. Methods: Apoptotic cell death after induced renal ischemia followed by reperfusion, was estimated in a group of Wistar albino rats by immunoflourescence and ELISA techniques. N-acetylcystein, an antioxidant agent, was given to the rats to study the effect on apoptosis. Tissues were examined immunohistochemically at 0, 1 h, 24 h, 5 days and 10 days for detection of apoptotic cells. Results: Our results showed that an ischemia for 60 min followed by reperfusion for 60 min triggered apoptosis. Moreover, N-acetylcystein significantly diminished both the ischemia/reperfusion damage and apoptosis. Conclusion: We anticipate our results would be important for kidney transplantation in estimating the critical time point for apoptosis and administration of N-acetylcystein prior to removal of the organ may be important in delaying the onset of apoptosis